22 22. Trottier BJ, Burns LJ, Defor TE, et al. Association of iron overload with allogeneic hematopoietic cell transplantation outcomes: a prospective cohort study using R2‐MRI‐measured liver iron content. Blood. 2013; 122:1678–1684.
23 23. St Pierre TG, Clark PR, Chua‐anusorn W, et al. Noninvasive measurement and imaging of liver iron concentrations using proton magnetic resonance. Blood. 2005; 105(2):855–861.
24 24. Majhail NS, DeFor T, Lazarus HM, Burns LJ. High prevalence of iron overload in adult allogeneic hematopoietic cell transplant survivors. Biol Blood Marrow Transplant. 2008; 14(7):790–794.
25 25. Angelucci E, Muretto P, Lucarelli G, et al. Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients. Blood. 1997; 90(3):994–998.
26 26. Mariotti E, Angelucci E, Agostini A, et al. Evaluation of cardiac status in iron‐loaded thalassaemia patients following bone marrow transplantation: improvement in cardiac function during reduction in body iron burden. Br J Haematol. 1998; 103(4):916–921.
27 27. Cooke KR, Luznik L, Sarantopoulos S, et al. The biology of chronic graft‐versus‐host disease: A task force report from the National Institutes of Health consensus development project on criteria for clinical trials in chronic graft‐versus‐host disease. Biol Blood Marrow Transplant. 2017; 23(2):211–234.
28 28. Baird K, Cooke K, Schultz KR. Chronic graft‐versus‐host disease (GVHD) in children. Pediatr Clin North Am. 2010; 57(1):297–322.
29 29. Zecca M, Prete A, Rondelli R, et al. Chronic graft‐versus‐host disease in children: incidence, risk factors, and impact on outcome. Blood. 2002; 100(4):1192–1200.
30 30. Arora M, Cutler CS, Jagasia MH, et al. Late acute and chronic graft‐versus‐host disease after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2016; 22(3):449–455.
31 31. Cuvelier GDE, Nemecek ER, Wahlstrom JT, et al. Benefits and challenges with diagnosing chronic and late acute GVHD in children using the NIH consensus criteria. Blood. 2019; 134(3):304–316.
32 32. Norkin M, Shaw BE, Brazauskas R, et al. Characteristics oflate fatal infections after allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2019; 25(2):362–368.
33 33. Inamoto Y, Storer BE, Petersdorf EW, et al. Incidence, risk factors and outcomes of sclerosis in patients with chronic graft‐versus‐host disease. Blood. 2013; 121(25):5098–5103.
34 34. Inamoto Y, Pidala J, Chai X, et al. Assessment of joint and fascia manifestations in chronic graft‐versus‐host disease. Arthritis and Rheumatology. 2014; 66(4):1044–1052.
35 35. Inamoto Y, Lee SJ, Onstad LE, et al. Refined National Institutes of Health response algorithm for chronic graft‐versus‐host disease in joints and fascia. Blood Adv. 2020; 4(1):40–46.
36 36. Carpenter PA, Kitko CL, Elad S, et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft‐versus‐Host Disease: V. The 2014 Ancillary Therapy and Supportive Care Working Group Report. Biol Blood Marrow Transplant. 2015; 21(7):1167–1187.
37 37. Rubin LG, Levin MJ, Ljungman P, et al. 2013 IDSA clinical practice guideline for vaccination of the immunocompromised host. Clin Infect Dis. 2014; 58(3):e44–100.
38 38. Carpenter PA, Englund JA. How I vaccinate blood and marrow transplant recipients. Blood. 2016; 127(23):2824–2832.
39 39. Five things physicians and patients should question. Choosing Wisely ‐ An initiative of the ABIM Foundation. Available from: https://www.choosingwisely.org/wp‐content/uploads/2018/01/ASTCT‐CTTC‐Choosing‐Wisely‐List_2019.pdf (accessed 24 August 2020).
40 40. Suh DW, Ruttum MS, Stuckenschneider BJ, et al. Ocular findings after bone marrow transplantation in a pediatric population. Ophthalmology. 1999; 106(8):1564–1570.
41 41. Lee SJ, Wolff D, Kitko C, et al. Measuring therapeutic response in chronic graft‐versus‐host disease. National Institutes of Health consensus development project on criteria for clinical trials in chronic graft‐versus‐host disease: IV. The 2014 Response Criteria Working Group report. Biol Blood Marrow Transplant. 2015; 21(6):984–999.
42 42. Galbán CJ, Boes JL, Bule M, et al. Parametric response mapping as an indicator of bronchiolitis obliterans syndrome after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2014; 20(10):1592–1598.
43 43. Bergeron A, Chevret S, Chagnon K, et al. Budesonide/Formoterol for bronchiolitis obliterans after hematopoietic stem cell transplantation. Am J Respir Crit Care Med. 2015; 191(11):1242–1249.
44 44. Baker KS, Chow E, Steinberger J. Metabolic syndrome and cardiovascular risk in survivors after hematopoietic cell transplantation. Bone Marrow Transplant. 2012; 47(5):619–625.
45 45. Meacham LR, Chow EJ, Ness KK, et al. Cardiovascular risk factors in adult survivors of pediatric cancer‐‐a report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev. 2010; 19(1):170–181.
46 46. Shalitin S, Phillip M, Stein J, et al. Endocrine dysfunction and parameters of the metabolic syndrome after bone marrow transplantation during childhood and adolescence. Bone Marrow Transplant. 2006; 37(12):11091117.
47 47. Baker KS, Ness KK, Steinberger J, et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood. 2007; 109(4):1765–1772.
48 48. Chow EJ, Baker KS, Lee SJ, et al. Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation. J Clin Oncol. 2014; 32(3):191–198.
49 49. The Childhood Cancer Survivor Study: CCSS Cardiovascular Risk Calculator: St. Jude Childrens' Research Hospital. Available from: https://ccss.stjude.org/cvcalc (accessed 24 August 2020).
50 50. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Eng J Med. 1995; 333(10):621–627.
51 51. Mahle WT, Vincent RN, Berg AM, Kanter KR. Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation. J Heart Lung Transplant. 2005; 24(1):63–66.
52 52. Argent E, Kainer G, Aitken M, et al. Atorvastatin treatment for hyperlipidemia in pediatric renal transplant recipients. Pediatr Transplant. 2003; 7(1):38–42.
53 53. Cosio FG, Pesavento TE, Pelletier RP, et al. Patient survival after renal transplantation III: the effects of statins. Am J Kidney Dis. 2002; 40(3):638–643.
54 54. Wang GJ, Cui Q, Balian G. The Nicolas Andry award. The pathogenesis and prevention of steroid‐induced osteonecrosis. Clin Orthop Relat Res. 2000( 370):295–310.
55 55. Pritchett JW. Statin therapy decreases the risk of osteonecrosis in patients receiving steroids. Clin Orthop Relat Res. 2001( 386):173–178.
56 56. Prasad GV, Ahmed A, Nash MM, Zaltzman JS. Blood pressure reduction with HMG‐CoA reductase inhibitors in renal transplant recipients. Kidney Int. 2003; 63(1):360–364.
57 57. Prasad GV, Chiu R, Nash MM, Zaltzman JS. Statin use and bone mineral density in renal transplant recipients. Am J Transplant. 2003; 3(10):1320–1321.
58 58. Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy (Review). Curr Med Res Opin. 2003; 19(6):540–556.
59 59. Fehr T, Kahlert C, Fierz W, et al. Statin‐induced immunomodulatory effects on human T cells in vivo. Atherosclerosis. 2004; 175(1):83–90.
60 60.